Lab
Ohrelle Laboratories INC
Ohrelle Laboratories INC was paid $6.17M by Medicaid between Dec 2021 and Dec 2024, across 12 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 52% of everything it billed.
33Billing provider infoOHRELLE LABORATORIES INC
BEVERLY HILLS, CA 90211
BEVERLY HILLS, CA 90211
33aNPI1871248096assigned 02/16/2022
33bProvider typeClinical Medical Laboratory
28Total paid$6.17M
24GClaims163,750
24DCodes billed12
24AFirst – last monthDec 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#100 of 561
Median peer was paid$222K
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 102 | $2K | |
| 2022 | 23,008 | $934K | |
| 2023 | 43,820 | $1.96M | |
| 2024incomplete | 96,820 | $3.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 52% | 76,485 | 22,735 | $3.18M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 15% | 12,482 | 8,544 | $897K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12% | 19,857 | 11,568 | $716K |
| 87634 | 9.6% | 19,841 | 11,550 | $595K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.1% | 12,508 | 8,539 | $252K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.6% | 12,313 | 6,930 | $220K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.4% | 7,683 | 5,249 | $148K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 948 | 604 | $80K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 398 | 381 | $58K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 411 | 393 | $8K |
| 87486 | <1% | 411 | 395 | $6K | |
| 87581 | <1% | 413 | 396 | $6K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFARAH, MICHAEL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Regenerate Ghods, INC | Los Angeles, CA | $12K |
| Refael Medical, INC. | Beverly Hills, CA | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.